PharmiWeb.com - Global Pharma News & Resources
25-Jan-2019

Chronic Plaque Psoriasis Pipeline Insight Report 2019 - ResearchAndMarkets.com

The "Chronic Plaque Psoriasis - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Chronic Plaque Psoriasis - Pipeline Insight, 2019 report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Chronic Plaque Psoriasis development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

  • Clinical
  • Non-clinical
  • Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Chronic Plaque Psoriasis

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Chronic Plaque Psoriasis

The report assesses the active Chronic Plaque Psoriasis pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • The report provides a snapshot of the pipeline development for Chronic Plaque Psoriasis
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Chronic Plaque Psoriasis
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Chronic Plaque Psoriasis
  • The report also covers the dormant and discontinued pipeline projects related to Chronic Plaque Psoriasis

Companies Mentioned

  • Novartis Pharmaceuticals
  • Janssen Research & Development
  • UCB Biopharma
  • Pfizer
  • Cellceutix Corporation
  • AbbVie
  • Kadmon Corporation
  • UCB Biopharma
  • Biogen
  • AbGenomics
  • Glenmark Farmacutica Ltda
  • ApoPharma
  • ASIS Corporation
  • Elorac Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/rhdmr8/chronic_plaque?w=4

View source version on businesswire.com: https://www.businesswire.com/news/home/20190125005386/en/

Editor Details

Last Updated: 25-Jan-2019